Clinigen Group plc Director/PDMR Shareholding (6436E)
May 09 2017 - 10:47AM
UK Regulatory
TIDMCLIN
RNS Number : 6436E
Clinigen Group plc
09 May 2017
9 May 2017
Director's Share Dealing
Clinigen Group plc (AIM: CLIN, 'Clinigen' or the 'Group'), the
global pharmaceutical and services group, announces that it was
notified on 5 May 2017 that the following transactions took place
on 4 May 2017.
Peter George, Non-Executive Director, transferred 43,000
ordinary shares of 0.1 pence each in the Company at nil pence per
share.
Following this transaction, Mr George's total beneficial
interest in the Company is 3,314,242 ordinary shares, representing
approximately 2.88 per cent of the current issued share
capital.
The notification below, made in accordance with the requirements
of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
1 Details of the person discharging
managerial responsibilities/person
closely associated
---- -------------------------------------------------------
a) Name Peter George
---- ---------------------- -------------------------------
2 Reason for the notification
---- -------------------------------------------------------
a) Position/status Non-Executive Director
---- ---------------------- -------------------------------
b) Initial Initial Notification
notification
/Amendment
---- ---------------------- -------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform,
auctioneer or auction monitor
---- -------------------------------------------------------
a) Name Clinigen Group plc
---- ---------------------- -------------------------------
b) Legal Entity N/A
Identifier
---- ---------------------- -------------------------------
4 Details of the transaction(s): section
to be repeated for (i) each type
of instrument; (ii) each type of
transaction; (iii) each date; and
(iv) each place where transactions
have been conducted
---- -------------------------------------------------------
a) Description Ordinary shares of 0.1 pence
of the financial each
instrument, GB00B89J2419
type of
instrument
Identification
code
---- ---------------------- -------------------------------
b) Nature of Transfer of shares
the transaction
---- ---------------------- -------------------------------
c) Currency GBP
---- ---------------------- -------------------------------
d) Price(s) Price(s) Volume(s)
and volume(s)
---- ---------------------- -------------- ---------------
0p 43,000
--------------------------- -------------- ---------------
e) Aggregated 43,000
information
- Aggregated 0p
volume
- Price Nil
- Aggregated
total
--------------------------- -------------------------------
f) Date of 4 May 2017
the transaction
---- ---------------------- -------------------------------
g) Place of London Stock Exchange, AIM
the transaction
---- ---------------------- -------------------------------
-Ends-
Contact Details
Clinigen Group plc Tel: +44 (0) 1283
495 010
Shaun Chilton, Group Chief
Executive Officer
Martin Abell, Group Chief Financial
Officer
Numis Securities Limited Tel: +44 (0) 20
7260 1000
Michael Meade / Freddie Barnfield
(Nominated Adviser)
James Black / Tom Ballard
(Corporate Broking)
RBC Capital Markets - Joint Tel: +44 (0) 20
Broker 7653 4000
Marcus Jackson / Elliot Thomas
/ Jack Wood
Instinctif Partners (media Tel: +44 (0) 20
relations) 7457 2020
Melanie Toyne-Sewell / Alex
Shaw Email: clinigen@instinctif.com
About Clinigen Group
Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and
services company with a unique combination of businesses focused on
providing access to medicines. Its mission is to deliver the right
medicine to the right patient at the right time.
The Group consists of five synergistic businesses focused in
three areas of global medicine supply; clinical trial, unlicensed
and licensed medicines.
Clinigen Clinical Trial Services is the global market leader in
the management and supply of commercial medicines for clinical
trials.
The Group is also the trusted global leader in ethically
sourcing and supplying unlicensed medicines to hospital pharmacists
and physicians for patients with a high unmet need, through three
of its divisions: Idis Managed Access runs early access programmes
for innovative new medicines. Idis Global Access and Link
Healthcare work directly with healthcare professionals to enable
compliant access to unlicensed medicines on a global basis and
niche essential licensed and generic medicines across Australasia,
Africa and Asia (AAA region).
Clinigen Specialty Pharmaceuticals acquires global rights,
revitalises and markets its own portfolio of niche hospital
products.
For more information, please visit www.clinigengroup.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLLFSSESIAIID
(END) Dow Jones Newswires
May 09, 2017 10:47 ET (14:47 GMT)
Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024
Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024